Venture Capital & Emerging Companies

We know how to help you turn your ideas into reality. Our attorneys can provide you with legal services that evolve as your enterprise does — from start-up to successful exit. 

Because we work to understand your business, we’ll help examine your corporate requirements, intellectual property protection, employment issues, and regulatory and compliance needs, and assess how these impact your bottom line. That’s what we’ve already done for many major companies and investors in the information technology, digital media, social media, life sciences, health care, and energy and clean technology sectors.

We’re experienced in representing clients in all types of financings — from early- or seed-stage investments through later stages. We provide counsel to companies, investors, and financial advisors in a range of sophisticated transactions.

Quick Facts


  • More than 240 completed venture capital transactions since 2010, with an aggregate deal value of over $1.8 billion
  • Represent founders, companies, and venture capital and other investors
  • All stages — from early- or seed-stage investments through subsequent multi-investor and late-stage financing
  • Initiate introductions between our start-up clients and our network of angel investors and venture capital firms
  • Recommended by The Legal 500 United States for Mergers, Acquisitions and Buyouts - Venture Capital and Emerging Companies

Areas of Focus

  • Start-Up services
    • Incorporation
    • Intellectual property protection
    • Option plans
    • Proprietary information agreements
    • Restricted stock agreements
    • Stockholder agreements

  • Corporate transactions
    • Commercial contracts
    • International transactions
    • Joint ventures
    • Licensing
    • Mergers and acquisitions
    • Outsourcing agreements
    • Strategic alliances

  • Employee, labor, and benefits counseling
    • Compensation arrangements
    • Employee handbooks
    • Immigration
    • Noncompete protection

  • Financings
    • Alternative public offerings
    • Cross-border financings
    • Debt and equity structures
    • IPOs
    • Private placements
    • Seed stage and “angel” financings
    • Venture financings

  • Fund formation
    • Broker-dealer and investment advisor regulatory compliance
    • Investment advisory agreements
    • Limited liability company agreements
    • Limited partnership agreements
    • Private placement memoranda

  • Government relations
    • Federal government regulations
    • Lobbying

  • Intellectual property
    • Copyrights
    • Patents
    • Privacy and security
    • Technology transfer
    • Trademarks

  • Tax structuring and advice
    • Minimizing tax on equity grants
    • Structuring transactions

Sort by: Name  Title  Office

Boston 617.348.3084
Brady Berg

Brady Berg

Member

San Francisco 415.432.6003
New York 212.692.6869
Michael A. Brown

Michael A. Brown

Associate

New York 212.692.6809
Boston 617.348.3097
San Diego 858.314.1533
San Francisco 415.432.6000
Hannah C. Coman

Hannah C. Coman

Associate

Boston 617.348.1703
John P. Condon

John P. Condon

Associate

Boston 617.348.4453
Peter Demuth

Peter Demuth

Member

Boston 617.348.3008
New York 212.692.6223
Samuel Effron

Samuel Effron

Associate

New York 212.692.6810
Boston 617.348.1640
Boston 617.348.3051
Boston 617.348.1834
Kristin A. Gerber

Kristin A. Gerber

Associate

Boston 617.348.3043
San Diego 858.314.1515
San Francisco 415.432.6000
Boston 617.348.1623
Kanasha S. Herbert

Kanasha S. Herbert

Associate

Boston 617.348.3015
Boston 617.348.1715
Boston 617.348.3093
Boston 617.239.8491
New York 212.692.6768
San Diego 858.314.1509
San Francisco 415.432.6104
Washington, DC 202.434.7452
San Diego 858.314.1519
Boston 617.348.1841
R. Robert Popeo

R. Robert Popeo

Chairman

Boston 617.348.1716
Linda Rockett

Linda Rockett

Member

Boston 617.348.4888
Jake Romero

Jake Romero

Associate

San Diego 858.314.1584
Boston 617.348.1798
New York 212.692.6732
Bram Shapiro

Bram Shapiro

Member

Boston 617.348.1610
Sahir Surmeli

Sahir Surmeli

Member

Boston 617.348.3013
Jonathan Urbon

Jonathan Urbon

Associate

Boston 617.348.1844
Boston 617.348.1759
Garrett M. Winslow

Garrett M. Winslow

Associate

Boston 617.348.3028
Ran Zioni

Ran Zioni

International Member

Washington, DC 202.434.7456
Dean G. Zioze

Dean G. Zioze

Member

Boston 617.348.4795

Representative Experience

  • Represented ClearSky Power + Technology Fund I in the following 2012 financings: $5 million Series A financing of Sentient Energy, Inc.; $22.5 million Series D financing of iControl Networks, Inc.; and $17.55 million Series B financing of Modular Wind Energy, Inc.
  • Represented Intercept Pharmaceuticals, Inc. in its August 2012 $30 million Series C financing led by OrbiMed Advisors and Genextra.
  • Represented AccuVein, Inc. in its July 2012 $7.1 million financing led by MVM Life Sciences Fund, Bessemer Venture Partners, Tullis, and Lynch Foundation.
  • Represented Tarsa Therapeutics, Inc. in its March 2012 $28 million Series B financing led by Foresite Capital, Novo A/S, MVM Life Sciences Fund, and Quaker Partners.
  • Represented GreatPoint Energy, Inc. in its March 2012 $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Compass Labs, Inc. in its February 2012 $6 million financing led by Presidio Ventures and NEA (New Enterprise Associates).
  • Represented Extole, Inc. in its January 2012 $10.2 million financing led by Shasta Ventures, Trident Capital, Redpoint Ventures, and Norwest Venture Partners.
  • Represented Oxford Bioscience Partners in its December 2011 $20 million Series C financing of Glori Energy, a leader in sustainable, enhanced oil recovery and provider of the AERO (Activated Environment for Recovery of Oil) System. Gentry Venture Partners led the investment. Other investors included Advantage Capital Partners, Energy Technology Ventures (a GE, NRG Energy, and ConocoPhillips joint venture), GTI Ventures, Kleiner Perkins Caufield and Byers (KPCB), Malaysian Life Sciences Capital Fund, and the Omzest Group.
  • Represented Sera Prognostics, Inc. in its November 2011 $19.3 million Series A financing led by Interwest Partners, Domain Partners, Catalyst Health Ventures, Osage University Partners, and UpStart Life Sciences Capital.

Past